Escalated radiation dose doesn’t improve 8-year overall survival in intermediate-risk men (but does it matter?)

Last week, we saw that escalated dose did not improve 10-year overall survival in high-risk men (see this link). The latest published findings of the randomized clinical trial (RTOG 0126) prove that 8-year overall survival was not improved in intermediate-risk men who received a higher radiation dose. … READ MORE …

Recovery of normal serum T levels after short-term ADT and radiation therapy

Two matters of concern to many prostate cancer patients who are considering radiation therapy as a treatment for their prostate cancer are : (a) Should I be having a short course of androgen deprivation therapy (ADT) along with the radiation therapy? (b) How well will I recover normal serum testosterone levels after such short-term treatment? … READ MORE …

Why did biochemical control not translate into a survival increase after brachy boost therapy?

The first randomized clinical trial to prove that brachy boost radiotherapy had better oncological outcomes among high-risk patients was the one published by Sathya et al. in 2005. … READ MORE …

Predicting outcomes on active surveillance for intermediate-risk patients

It is now clear that men who meet NCCN criteria for very low- and low-risk forms of prostate cancer are almost invariably good candidates for initial management on active surveillance (i.e., just monitoring as opposed to immediate treatment). … READ MORE …

Brachy boost: the gold standard for progression-free survival of high-risk prostate cancer

Several randomized clinical trials have established the superior oncological outcomes of the combination of external beam radiotherapy with a high-dose-rate brachytherapy boost (see this link). … READ MORE …

Increasing acceptance of different types of “intermediate-risk” prostate cancer

A new review article in the journal Oncology provides us with an overview of the appropriate management of men with “favorable” and “unfavorable” forms of intermediate-risk prostate cancer. … READ MORE …

EBRT works better with ADT for intermediate- and high-risk prostate cancer

The EORTC trial 22991 was designed and implemented to compare external beam radiation therapy (EBRT) + short-term androgen deprivation therapy (ADT) to EBRT alone as first-line therapy in patients with intermediate- and high-risk prostate cancer. … READ MORE …